Editas Medicine Inc

NASDAQ:EDIT 4:00:00 PM EDT

2.72

-0.11 (-3.89%)

5:40:30 PM EDT: $2.78 +0.06 (+2.21%)

Market Cap (Intraday)	244.57M
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$4.94 Million
Adjusted EPS	-$0.30

See more estimates

10-Day MA	$2.70
50-Day MA	$2.74
200-Day MA	$1.89

See more pivots

Editas Medicine Inc Stock, NASDAQ:EDIT

11 Hurley Street, 11 Hurley Street, Cambridge, Massachusetts 02141

United States of America

Phone: +1.617.401.9000

Number of Employees: 246

http://www.editasmedicine.com

Description

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.